Posts

Showing posts with the label Fibrosarcoma market outlook

Fibrosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Fibrosarcomas are malignant neoplasms of fibroblasts with varying collagen production and a "herringbone" architecture. Fibrosarcomas typically originate from the fascia and soft tissue tendons but can also occur in bones as primary or secondary tumors in the medullary canal or periosteum. These tumors derive from a mesenchymal cell origin, composed of spindle-cell fibroblasts with uncontrolled proliferation. Fibrosarcomas are divided into infantile (rarely metastasizing) and adult-type (highly malignant). Previous bone damage or radiotherapy may increase the risk of fibrosarcoma of the bone. Surgical excision is the primary treatment for localized soft tissue sarcomas. Some diagnoses include low-grade fibromyxoid sarcomas, sclerosing epithelioid fibrosarcomas, fibrosarcomatous dermatofibrosarcoma protuberans, and synovial sarcomas, which may be mistaken for adult fibrosarcoma. Most adult fibrosarcomas (80%) are high-grade, with a survival rate of less than 70% at two yea...

Fibrosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
 Fibrosarcomas are malignant neoplasms of fibroblasts with varying collagen production and a "herringbone" architecture. Fibrosarcomas typically originate from the fascia and soft tissue tendons but can also occur in bones as primary or secondary tumors in the medullary canal or periosteum. These tumors derive from a mesenchymal cell origin, composed of spindle-cell fibroblasts with uncontrolled proliferation. Fibrosarcomas are divided into infantile (rarely metastasizing) and adult-type (highly malignant). Previous bone damage or radiotherapy may increase the risk of fibrosarcoma of the bone. Surgical excision is the primary treatment for localized soft tissue sarcomas. Some diagnoses include low-grade fibromyxoid sarcomas, sclerosing epithelioid fibrosarcomas, fibrosarcomatous dermatofibrosarcoma protuberans, and synovial sarcomas, which may be mistaken for adult fibrosarcoma. Most adult fibrosarcomas (80%) are high-grade, with a survival rate of less than 70% at two years ...